0330 FTC Illumina Grail
BioCentury & Getty Images

Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

Illumina will fight the suit, arguing it’s giving competitors a fair deal and benefitting the field as a whole

Illumina will fight the suit, arguing it’s giving competitors a fair deal and benefitting the field as a whole.

Mar 31, 2021 | 1:01 AM GMT

The FTC’s 4-0 vote to challenge Illumina’s pending $7.1 billion Grail acquisition aligns with acting agency Chair Rebecca Kelly Slaughter’s vow to expand scrutiny of biotech M&A beyond

Read the full 906 word article

How to gain access

Continue reading with a
two-week free trial.